LOXL2—A New Target in Antifibrogenic Therapy?
暂无分享,去创建一个
S. Llerena | J. Crespo | E. Fábrega | P. Iruzubieta | J. Cabezas | J. I. Fortea | P. Huelín | Á. Puente | M. T. Arias Loste | P. Huelin | J. Fortea | María Teresa Arias Loste | A. Puente
[1] M. Manns,et al. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease , 2019, Hepatology.
[2] J. Chan,et al. Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension , 2018, Hepatology.
[3] M. Karsdal,et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. , 2019, American journal of physiology. Gastrointestinal and liver physiology.
[4] D. Rockey,et al. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. , 2018, Gastroenterology.
[5] J. Ladero,et al. Liver fibrosis. , 2018, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
[6] Z. Goodman,et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial , 2017, Hepatology.
[7] X. Forns,et al. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. , 2017, Gastroenterology.
[8] L. Valenti,et al. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. , 2017, Clinical science.
[9] Y. Ilan,et al. Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic? , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[10] A. Benson,et al. A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma , 2017, The oncologist.
[11] A. Benson,et al. A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma , 2017, The oncologist.
[12] D. Schuppan,et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal , 2017, Gut.
[13] H. Collard,et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. , 2017, The Lancet. Respiratory medicine.
[14] Richard Moreau,et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. , 2017, Journal of hepatology.
[15] J. Crespo,et al. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. , 2017, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[16] Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.
[17] I. Ruiz-Trillo,et al. Origin and evolution of lysyl oxidases , 2015, Scientific Reports.
[18] J. Bosch,et al. Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. , 2015, Journal of hepatology.
[19] C. Trautwein,et al. Hepatic fibrosis: Concept to treatment. , 2015, Journal of hepatology.
[20] S. Friedman,et al. Pathobiology of liver fibrosis: a translational success story , 2015, Gut.
[21] I. Ng,et al. Lysyl oxidase‐like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma , 2014, Hepatology.
[22] F. Tacke,et al. Roles for chemokines in liver disease. , 2014, Gastroenterology.
[23] R. Ehman,et al. Role of magnetic resonance elastography in compensated and decompensated liver disease. , 2014, Journal of hepatology.
[24] Frank Tacke,et al. Macrophage heterogeneity in liver injury and fibrosis. , 2014, Journal of hepatology.
[25] J. Fallowfield,et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ , 2014, Nature Reviews Immunology.
[26] M. Robson,et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease , 2014, Journal of hepatology.
[27] Lan Wei,et al. Molecular MRI of collagen to diagnose and stage liver fibrosis. , 2013, Journal of hepatology.
[28] N. Kaminski,et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression , 2013, European Respiratory Journal.
[29] V. Paradis,et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. , 2013, Journal of hepatology.
[30] D. Schuppan,et al. Evolving therapies for liver fibrosis. , 2013, The Journal of clinical investigation.
[31] D. Rockey. Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[32] M. Manns,et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.
[33] J. Fallowfield,et al. Edinburgh Research Explorer Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis Differential Ly-6C expression identi fi es the recruited macrophage phenotype, which orchestrates the regression of murine liver fi brosis , 2022 .
[34] K. Iwaisako,et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. , 2012, Gastroenterology.
[35] A. Waisman,et al. Th17 cells regulate liver fibrosis by targeting multiple cell types: many birds with one stone. , 2012, Gastroenterology.
[36] Laurent Castera,et al. Noninvasive methods to assess liver disease in patients with hepatitis B or C. , 2012, Gastroenterology.
[37] B. Hinz,et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. , 2012, The American journal of pathology.
[38] T. Luedde,et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury , 2011, Gut.
[39] T. Wynn,et al. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. , 2011, American journal of physiology. Gastrointestinal and liver physiology.
[40] S. Friedman,et al. Pathogenesis of liver fibrosis. , 2011, Annual review of pathology.
[41] Derek Marshall,et al. Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment , 2010, Nature Medicine.
[42] Scott L. Friedman,et al. Evolving challenges in hepatic fibrosis , 2010, Nature Reviews Gastroenterology &Hepatology.
[43] J. Dranoff,et al. Portal fibroblasts: Underappreciated mediators of biliary fibrosis , 2010, Hepatology.
[44] T. Wynn,et al. Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent , 2010, The Journal of experimental medicine.
[45] F. Marra,et al. Mononuclear cells in liver fibrosis , 2009, Seminars in Immunopathology.
[46] Jaume Bosch,et al. Angiogenesis in liver disease. , 2009, Journal of hepatology.
[47] O. Pappo,et al. A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT , 2008, Journal of viral hepatitis.
[48] Yosuke Osawa,et al. TLR4 enhances TGF-β signaling and hepatic fibrosis , 2007, Nature Medicine.
[49] F. Marra,et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. , 2007, The American journal of pathology.
[50] H. Kagan,et al. Lysyl oxidase: an oxidative enzyme and effector of cell function , 2006, Cellular and Molecular Life Sciences CMLS.
[51] Quynh-Thu Le,et al. Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.
[52] G. D’Amico,et al. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.
[53] Oliver N Keene,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.
[54] J. Fallowfield,et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. , 2004, Gastroenterology.
[55] D. Rockey. Vascular mediators in the injured liver , 2003, Hepatology.
[56] T. Roskams,et al. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. , 2001, Journal of hepatology.
[57] J. Iredale,et al. Pathogenesis of liver fibrosis. , 1997, Clinical science.